Drug Profile
KUR 115
Alternative Names: KUR115Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Kuros Biosurgery
- Developer Kuros Biosciences
- Class Blood proteins; Peptide hormones; Serine endopeptidases
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for phase-I development in Bone-disorders in USA (Implant)
- 15 Oct 2015 Pharmacodynamics and adverse events data from a preclinical trial in Spinal fusion released by Kuros Biosurgery
- 08 Sep 2015 Phase-I clinical trials in Spinal fusion in USA (unspecified route) before September 2015